A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK

Trial Identifier: D4326C00004
Sponsor: AstraZeneca
Start Date: February 2024
Primary Completion Date: December 2024
Study Completion Date: December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Czech (Czech Republic) Translation
German (Germany) Translation
English (Australia) Translation
English (Belgium) Translation
English (United Kingdom) Translation
Spanish (United States) Translation
French (Belgium) Translation
Italian (Italy) Translation
Japanese (Japan) Translation
Dutch (Belgium) Translation
Polish (Poland) Translation
Slovak (Slovakia) Translation

Trial Locations

Country Location
AU Adelaide, AU, 5000
AU Kogarah, AU, 2217
AU Mitcham, AU, 3132
BE Mechelen, BE, 2800
CZ Liberec, CZ, 460 63
CZ Mladá Boleslav, CZ, 293 01
CZ Praha, CZ, 140 21
DE Leipzig, DE, 04103
DE Tuebingen, DE, 72076
GB Aberdeen, GB, AB25 2ZN
GB Hull, GB, HU3 2KZ
GB Ipswich, GB, IP4 5PD
GB London, GB, SE5 9RS
GB Nottingham, GB, NG7 2UH
IT Milano, IT, 20122
IT Padova, IT, 35128
IT Roma, IT, 00168
JP Gifu-shi, JP, 500-8513
JP Kawasaki-shi, JP, 215-0026
JP Kitakyusyu-shi, JP, 806-8501
JP Nagaoka-shi, JP, 940-2085
JP Niigata-shi, JP, 951-8520
JP Sapporo-shi, JP, 006-8555
JP Yokohama-shi, JP, 236-0004
PL Bydgoszcz, PL, 85-794
PL Katowice, PL, 40-081
PL Mysłowice, PL, 41-400
PL Poznań, PL, 61-848
SK Bratislava, SK, 83104
SK Nitra, SK, 950 01
SK Trnava, SK, 91702
US, CO Englewood, CO, US, 80113
US, SC Charleston, SC, US, 29425
US, TX San Antonio, TX, US, 78215